Precision Medicine Management of Chronic Lymphocytic Leukemia

Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Valentina Ferri(University of Turin), Mattia Schipani(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sruthi Sagiraju(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Chiara Favini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Wael Al Essa(General Organization For Teaching Hospitals and Institutes)
Cancers
March 10, 2020
10.3390/cancers12030642
Cited by 38

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases
|Biomaterials Research|2016|511
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|216